PHENYLBUTAZONE THERAPY OF ARTHRITIS AND OTHER PAINFUL MUSCULOSKELETAL DISORDERS

Publisher Website
Google Scholar
Abstract
This report describes our initial clinical observations on the administration of phenylbutazone (butazolidin®) and of phenylbutazone combined with aminopyrine ("butapyrin") in rheumatoid arthritis and other painful musculoskeletal disorders. These substances were submitted to us for investigation of their reputed analgesic and anti-inflammatory properties in articular and related painful conditions.1 Owing to the widespread interest already aroused in this country regarding these compounds, we are reporting these early results of our trials of these drugs. Even with the recent contributions of cortisone and corticotropin (ACTH) to the management of the rheumatic disorders, and the availability of other therapeutic agents, there are still many patients for whom these measures are contraindicated or ineffective for one reason or another. In such cases, therefore, there remains a real need for a sound and useful therapeutic preparation, even if its action proves merely palliative. Recently the synthetic derivative of pyrazol, called phenylbutazone (3,5-dioxo-1,2 diphenyl-4-n

This publication has 1 reference indexed in Scilit: